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ABSTRACT 
 
Purpose: Activation of the innate immune system plays a significant role in pathologies of the central 
nervous system (CNS). In order to follow disease progression and evaluate effectiveness of potential 
treatments involved in neuroinflammation, it is important to track neuroinflammatory markers in vivo 
longitudinally. The translocator protein (TSPO) is used as a target to image neuroinflammation as its 
expression is upregulated in reactive glial cells during CNS pathologies. However, it remains unclear 
in which microglial phenotypes TSPO levels are upregulated, as microglia can display a plethora of 
activation states that can be protective or detrimental to the CNS.  
Procedures: We assessed the levels of TSPO transcripts in cultured microglia that were polarized into 
pro- and anti-inflammatory states in vitro and in the brain of mice in which an anti-inflammatory 
environment was induced in vivo. In addition, we used a mouse model of peroxisomal multifunctional 
protein-2 (MFP2) deficiency that exhibits widespread neuroinflammation despite no neuronal loss and 
monitored TSPO expression by immunohistochemistry and by imaging using the TSPO radiotracer 
[18F]DPA-714.  
Results: TSPO expression was selectively increased in so-called classically activated or M1 microglia 
but not in alternatively activated or M2 microglia in vitro. In agreement, TSPO transcript levels were 
not induced in an anti-inflammatory brain environment. We found that both transcript and protein levels 
of TSPO are significantly increased in the brain of Mfp2-/- compared to control mice and TSPO 
immunoreactivity colocalized predominantly with microglia in Mfp2-/- brain. In vitro and ex vivo 
autoradiography in Mfp2-/- mice using the TSPO radiotracer [18F]DPA-714, confirmed increased 
expression of TSPO. These data demonstrate that TSPO imaging reveals microgliosis in non-
neurodegenerative brain pathologies.  
Conclusions: We show that induced TSPO expression marks a pro-inflammatory brain environment 
that is not necessarily accompanied by neuronal loss. 
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INTRODUCTION 
The innate immune system is implicated in all neurodegenerative disorders. Key players in 
neuroinflammatory processes are microglia and astrocytes. They become reactive, typically change 
their morphology and acquire modified functions [1, 2]. Neuroinflammation often precedes neuronal 
loss in neurodegenerative disorders such as in Alzheimer’s disease (AD) and Parkinson’s disease 
(PD) [3, 4]. Therefore, it is important to detect neuroinflammatory processes in presymptomatic stages 
as they mark early stages of neuropathology. The most studied biomarker for imaging of 
neuroinflammation is the 18 kDa translocator protein (TSPO), previously known as the peripheral 
benzodiazepine receptor (PBR), which is primarily expressed on the outer mitochondrial membrane of 
microglia and macrophages [5, 6]. TSPO is important for brain development and homeostasis during 
adulthood as it plays a crucial role in neurosteroidogenesis [7, 8]. TSPO expression in the CNS is low 
under healthy circumstances, but increases mainly in microglia in response to neuronal insults such as 
in the neurodegenerative diseases PD, AD, Amyotrophic lateral sclerosis (ALS), and Huntington 
disease (HD) [9, 10]. Reactive astrocytes can also induce TSPO expression in addition to reactive 
microglia [11].  
 
It is still a matter of debate whether neuroinflammation accelerates or delays disease progression in 
neurological disorders. Reactive microglia play Janus-like roles in neurological disorders. During 
pathology, activated microglia can promote tissue injury (denoted as an M1 phenotype) but also tissue 
repair and remodelling (denoted as an M2 phenotype), dependent on type of disease and stage of 
disease progression [12, 13]. Therefore, it is important to precisely characterise neuroinflammation in 
vivo in order to apply anti-inflammatory therapies only during harmful functioning of the innate immune 
system. Although TSPO is generally accepted as an appropriate marker of neuroinflammation, the 
functional link between TSPO and neuroinflammation remains unknown. It is unclear whether 
increased TSPO expression is associated with pro-inflammatory and neurotoxic responses (classically 
activated or M1 microglia), or with anti-inflammatory responses and tissue repair (alternatively 
activated or M2 microglia), or both. Whereas the association of TSPO with specific inflammatory states 
is poorly documented [14], this information is necessary to correctly interpret increased TSPO levels in 
vivo in clinical conditions and to adapt inflammatory therapies according to the need and disease 
stage of patients.  
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In this study, we aimed to better define in which neuroinflammatory conditions TSPO is induced. First, 
microglia were isolated from wild type brain and TSPO transcript expression was analyzed after 
polarization of the microglia into a pro- or anti-inflammatory state. This was complemented by an in 
vivo study in which an anti-inflammatory brain environment was created by intracerebroventricular 
(i.c.v.) injection of IL-4. In addition, we used a mouse model of peroxisomal β-oxidation deficiency, 
more specifically multifunctional protein-2 (MFP2) deficient mice, which develop robust and chronic 
neuroinflammation before the age of 8 weeks that progressively increases until death around the age 
of 17 weeks [15-17]. The mechanisms underlying this widespread gliosis were not elucidated yet but 
likely an interplay of cell-autonomous deregulation due to loss of MFP2 in microglia and microglial 
reactivity to neuronal dysfunction are involved [15,16]. Different from most other neuropathological 
disease models in which neuroinflammation develops, Mfp2-/- mice do not show neuronal loss [17]. We 
previously characterized the proliferative Mfp2-/- microglia extensively and found that they are of local 
origin, are immunologically activated but display a mixed pro- (M1) and anti- (M2) inflammatory 
phenotype [17]. Of note, they do not express detrimental neuroinflammatory markers such as iNOS. 
We investigated whether TSPO is induced in this inflamed but non-neurodegenerative brain 
environment by immunohistological and gene expression studies and by in vitro, ex vivo and in vivo 
TSPO imaging using the TSPO specific radiotracer [18F]DPA-714.   
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MATERIALS AND METHODS 
 
Mouse breeding 
Mfp2-/- mice were generated as previously described [18]. Mfp2-/- mice were bred on a Swiss/Webster 
background in a specific pathogen free animal housing facility of the KU Leuven, had ad libitum 
access to water and standard rodent food, and were kept on a 12-hour light and dark cycle. All animal 
experiments were performed in accordance with the "Guidelines for Care and Use of Experimental 
Animals" and fully approved by the Research Ethical committee of the KU Leuven (#190/2012). Both 
wild type and heterozygous mice were used as controls as no differences were detected in our 
previous investigations [15-17]. 
 
Immunohistochemistry 
Anesthesia of the mice and tissue processing for immunohistochemical (IHC) staining were performed 
as described [19]. Paraffin sections (7 µm) were used for immunofluorescent staining. The following 
primary antibodies were used: polyclonal rabbit anti-Iba1 (1:500; Wako D19-19741), rabbit anti-PBR 
(TSPO) (1:100; Abcam ab109497), rabbit anti-GFAP (1:200; Sigma G9269). After overnight incubation 
with primary antibodies at room temperature, HRP-labeled secondary antibodies (1:200) were applied 
for 1 hour, followed by fluorescent labeling with a cyanine 2 (FITC) TSA kit (Perkin Elmer Life 
sciences, Boston, USA). When double immunolabeling was performed, sets of primary and secondary 
antibodies were applied sequentially. The cyanine 3 TSA kit (Perkin Elmer Life sciences) was used as 
second fluorescent label. Images were acquired with a motorized inverted IX-81 microscope 
connected to a CCD-FV2T digital camera (Olympus, Aartselaar, Belgium) and processed with LSM 
Image browser software (Zeiss, Germany).  
 
Quantitative real time (qRT-)PCR 
RNA was extracted from cultured microglia using the PureLink RNA Mini Kit according to the 
manufacturer’s protocol and converted to cDNA using the Qiagen QuantiTect Reverse Transcription 
Kit. RNA was isolated from frontal cortex by using Trizol extraction following the manufacturer’s 
instructions (Thermofisher). 
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Real time PCR was performed as previously described [20] using an ABI PRISM 7500 Real Time PCR 
instrument (Applied Biosystems, Lennik, Belgium). Sets of validated primers and probes were ordered 
from Integrated DNA Technologies (IDT, Leuven, Belgium) or from Applied Biosystems (primer and 
probe sequences are listed in Suppl. Table 1). Assays were performed in triplicate in 10 µL TaqMan 
Fast Universal PCR Master Mix (Applied Biosystems). Relative expression levels of the target genes 
were calculated taking into account the amplification efficiency as described [21]. The relative 
expression levels of the target genes were calculated as a ratio to the housekeeping gene β-actin. 
Statistics were carried out using Graphpad Prism v5.0 software (San Diego, CA). 
 
Primary microglial cell culture 
For the preparation of primary microglia cultures, control mice from C57BL6/J background were used. 
The cultures were derived from the cortices of mice at postnatal day 0-1 as previously described [22]. 
Briefly, mice where decapitated and cortices dissected. After removal of the meninges, cortices were 
mechanically dissociated and the cell suspension was diluted with low glucose DMEM supplemented 
with 10% fetal bovine serum and 0.01% penicillin-streptomycin and cultured in T75 flasks. At day 14 in 
vitro microglia cells were isolated by shaking and rinsing the flasks. The purity of obtained cultures 
was confirmed by Cd11b flow-cytometry and found to be higher than 95% (Suppl. Fig 1).  
For RNA isolation microglia cells were plated in a 12-well plate at a density of 500 000 cells/well. One 
day after plating, cells were stimulated for 24h with vehicle (PBS 10 µl/ml), lipopolysaccharides (LPS) 
(1 µg/ml, Sigma Aldrich) or IL-1β/IFNγ (IL-1 β: 50 ng/ml; IFNγ: 20 ng/ml, R&D), or IL-4 (20 ng/ml, 
Sigma Aldrich) in order to shift them to the M0, M1 and M2 phenotype, respectively.  
 
Intracerebroventricular injections 
Male mice (15-16 weeks old) with a C57BL/6NTac background were used for i.c.v. injections with IL-4 
as described previously [23]. Mice were anesthetized with ketamine and xylazine (100 and 10 mg/kg 
respectively) and injected with vehicle (0.9% NaCl) or 200 ng IL-4 (R&D) in a total volume of 2.5 µl in 
the third cerebral ventricle using the following stereotaxic coordinates: bregma, −0.25 mm; lateral, 1 
mm; depth, 2.25 mm. The animals were allowed to recover for 20 h, after which they were sacrificed 
with an overdose of dormitor and nimatek (1 mg and 100 mg/kg, respectively). The frontal cortex 
contralateral to the injection site was collected and snap frozen in liquid nitrogen.  
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In vitro autoradiography  
Mice (n=3/group) were sacrificed at an age of 19 weeks, brain was removed, rinsed with saline to 
remove blood, rapidly frozen in 2-methylbutane (-40 °C) and stored at -20 °C for 24 h. Brain sagittal 
sections were obtained using a cryotome (Shandon cryotome FSE; Thermo Fisher, Waltham, USA), 
mounted on adhesive microscope slides (Superfrost Plus; Thermo Fisher) and stored at -20 °C until 
autoradiography was performed. Brain slices were dried and pre-incubated in tris-HCl 50 mM buffer 
(pH 7.4) for 10 min at room temperature. Before incubation with [18F]DPA-714, the brain sections were 
dried. The brain sections were incubated with 300 kBq (in 500 µL tris HCl 50 mM buffer) of tracer for 
10 min or tracer in the presence of 20 μM of the blocking agent PK11195 (Sigma Aldrich, St. Louis, 
MO, USA) for 10 min. The brain sections were washed twice for 10 min in tris-HCl 50 mM (pH 7.4) and 
0.3% BSA buffer at 4 °C. After a quick dip in water at 4 °C, the slides were dried. Autoradiograms 
were obtained by exposing the slides for 5 min to a high-performance phosphor storage screen 
(super-resolution screen; Perkin Elmer, Waltham, USA). The screens were read using a Cyclone Plus 
system (Perkin Elmer) and analyzed using Optiquant software (Perkin Elmer). The radioactivity 
concentration in the autoradiograms is expressed in digital light units (DLU)/mm², corrected for 
background. All statistical studies were performed with the unpaired two-tailed student t-test. 
Calculations were carried out using GraphPad Prism v5.0 (San Diego, CA). 
 
Ex vivo autoradiography 
Mice (16 weeks old, n=6/group) were injected with the tracer (22 ± 0.6 MBq, mean ± SD) via a tail vein 
under anesthesia (2.5% isoflurane in O2 at 1 L/min flow rate) and were kept under anesthesia until 
they were sacrificed by decapitation at 30 min (n=3/group) and 60 min (n=3/group) post tracer 
injection. Brain was removed and rapidly frozen in 2-methylbutane (between -30 °C and -40 °C). 20 
µm sagittal sections from brain were obtained using a cryotome (Shandon cryotome FSE, Thermo 
Fisher, Waltham, USA), mounted on adhesive microscope slides (Superfrost Plus, Thermo Fisher 
Scientific) and exposed to a phosphor storage screen film (super resolution screen; Perkin Elmer, 
Downers Grove, IL, USA) for 35 min. The screens were read using a Cyclone® Plus system (Perkin 
Elmer) and analyzed using Optiquant software (Perkin Elmer). The results were expressed as 
DLU/mm2 normalized for body weight of the animal and injected dose [(DLU/mm2) * (body 
weight/injected dose)]. 
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microPET 
Imaging experiments were performed on a Focus 220 microPET scanner (Concorde Microsystems, 
Knoxville, TN, USA). Six Mfp2-/- (26.5 ± 2.7 g, mean ± SD) and six control mice (39.8 ± 5.9 g) were 
scanned at end stage of disease, between 14 and 19 weeks of age. Mice were injected with 22 ± 0.6 
MBq (mean ± SD) of [18F]DPA-714 via a tail vein (volume injected <0.3 mL). During all PET sessions, 
animals were kept under gas anesthesia (2.5% isoflurane in O2 at a flow rate of 1 L/min). List-mode 
90-min microPET scans were acquired. Acquisition data were then Fourier rebinned in 24 time frames 
(4 x 15 seconds (s), 4 x 60 s, 5 x 180 s, 8 x 300 s, 3 x 600 s) and reconstructed using maximum a 
posteriori iterative reconstruction. The images were spatially aligned to a rat brain [18F]FDG template 
in Paxinos coordinates [24] using an affine transformation, allowing the use of a predefined volumes of 
interest map. Time-activity curves (TAC) were generated for total brain for each individual scan using 
PMOD software (version 3.2; PMOD technologies, Zurich, Switzerland).   
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RESULTS 
Induced TSPO expression is restricted to classically (M1) activated microglia  
It is known that activated microglia exert dual functions, either pro-inflammatory (M1) functions that are 
rather harmful, or anti-inflammatory (M2) functions that are neuroprotective and regenerative [25]. 
While this M1-M2 distinction is an oversimplification and represents the extreme states, this 
subdivision is a nice strategy to associate certain disease phenomena with a specific activation state 
of microglia. Although TSPO is a well-known marker for general neuroinflammation, it is still unknown 
whether TSPO expression is induced during both pro- and anti-inflammatory activation states of 
microglia or during a specific activation state only.  In this study, we aimed to associate induced TSPO 
expression with either a pro-inflammatory (M1) or anti-inflammatory (M2) activation state of microglia. 
First, cultured primary microglia isolated from newborn wild-type mice were polarized into a pro-
inflammatory phenotype by using either LPS or the combination of Interleukin (IL)-1β and Interferon 
gamma (IFNγ). Alternatively, they were brought into an anti-inflammatory state by treating with IL-4 
[26-28]. We verified that LPS and IL-1β/IFNγ polarizes the microglia towards an M1 state by showing 
increased transcript expression of the pro-inflammatory markers Tnfa (Fig. 1a and Suppl. Fig. 2a) and 
iNOS (Fig. 1b and Suppl. Fig. 2b) compared to vehicle-treated (M0) microglia whereas the M2 marker 
arginase-1 (Arg1) remained barely detectable (Fig. 1c and Suppl. Fig. 2c). Successful polarization to 
the M2 state with IL-4 was shown by strongly increased arginase-1 (Arg1) expression (Fig. 1c) and 
levels of iNOS and Tnfa that were unaltered compared to the M0 condition  [26]. We found that Tspo 
transcript expression was induced in both groups of M1-activated microglia but did not change in M2-
activated microglia (Fig. 1d and Suppl. Fig. 2d). Subsequently, we questioned whether the selective 
induction of TSPO in pro-inflammatory microglia in vitro also occurred in neuro-inflammatory 
conditions in vivo. We and others previously showed that TSPO expression is increased in models in 
which pro-inflammatory microglia predominate [29-31]. To induce an anti-inflammatory brain 
environment, we injected Il-4 in the third ventricle as previously reported [23, 32]. The expression of 
Tspo as well as of pro- and anti-inflammatory markers was assessed 20h later in the frontal cortex [23, 
32]. As expected, the overall profile of inflammatory markers coincided rather with an anti-
inflammatory than with a pro-inflammatory state (Fig. 2a-g). In this particular condition, in which neuro-
inflammation was clearly established, expression of Tspo transcripts were unaltered (Fig. 2h). 
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Together, these data demonstrate that Tspo expression is not induced in all inflammatory brain 
environments but rather marks a pro-inflammatory state. 
 
TSPO transcript and protein levels are induced in Mfp2-/- brain 
We previously demonstrated that in MFP2-deficient brain a robust and chronic neuroinflammation 
develops that is not accompanied by overt loss of neurons [17]. In order to analyse whether TSPO 
expression is increased in the CNS of Mfp2-/- mice, we first examined the transcript levels. Quantitative 
RT-PCR showed increased Tspo mRNA in brainstem of Mfp2-/- mice as compared to control mice at 
an age of 12 weeks (Fig. 3a). To ascertain that increased transcript levels are translated at the protein 
level, IHC was performed. Whereas TSPO immunoreactivity was hardly detectable in healthy control 
brain, TSPO was easily visualized throughout the whole Mfp2-/- brain (shown for brainstem, colliculus 
and thalamus in Fig. 3b-g). 
  
Upregulated TSPO colocalizes predominantly with reactive microglia in Mfp2-/- brain 
Increased TSPO expression was generally considered to be dedicated to microglia, but recent 
literature suggests a potential contribution of reactive astrocytes [11, 33, 34]. In order to assess 
whether microglia, astrocytes or both contribute to increased TSPO levels in Mfp2-/- brain, IHC staining 
of TSPO protein with cell type-specific markers (Iba1 for microglia and GFAP for astrocytes) was 
performed. Nearly all Iba1+ microglia express TSPO in Mfp2-/- brain (shown for colliculus in Fig. 3i) 
whereas only few GFAP+ astrocytes show TSPO expression (marked by arrows, Fig. 3k), indicating 
that increased TSPO levels are mainly attributed to reactive microglia in the Mfp2-/- brain.  
 
Increased [18F]DPA-714 uptake in Mfp2-/- brain: In vitro assessment of brain TSPO levels 
In order to evaluate whether increased expression of TSPO in Mfp2-/- brain could also be detected by 
using radiolabeled ligands for this protein, in vitro autoradiography employing [18F]DPA-714, an 
established PET tracer for TSPO, was used in a first approach. The results showed significantly higher 
tracer binding in the Mfp2-/- brain as compared to age-matched control brain (P < 0.0001; Fig. 4a,b). 
More specifically, high binding of [18F]DPA-714 was observed in colliculus, brainstem, corpus callosum 
and hippocampus mirroring the immunofluorescent detection of TSPO (Fig. 4a). We performed a 
blocking study using PK11195 (20 µM) as a blocking agent on brain slices of Mfp2-/- mice. PK11195 
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significantly reduced [18F]DPA-714 binding (P<0.0001; Fig. 4c), demonstrating TSPO-specific binding 
of [18F]DPA-714. 
 
Increased [18F]DPA-714 uptake in Mfp2-/- brain: Ex vivo assessment of brain TSPO levels 
Ex-vivo autoradiography was used to verify whether the increased TSPO expression observed in vitro 
is sufficient to be detected after intravenous injection of [18F]DPA-714.  Ex-vivo autoradiography has a 
10-fold higher resolution than microPET and is therefore more sensitive to reveal increased tracer 
concentration in small brain areas. Analysis of the ex vivo autoradiography data showed significantly 
higher tracer binding in the Mfp2-/- brain as compared to the age-matched control brain both at 30 min 
(P = 0.0017) and 60 min (P < 0.0001) after [18F]DPA-714 injection (Fig. 4d-g). 
 
MicroPET: In vivo assessment of brain TSPO levels  
Although the resolution of the microPET scanner (1.4 mm FWHM in the centre) is low relative to the 
brain size of mice so that partial volume effects may obscure increase of tracer binding in small brain 
areas, we explored whether we would be able to detect increased [18F]DPA-714 binding in vivo in 
Mfp2-/- mice compared to control mice. Figure 5 shows the TACs and brain images of the microPET 
scan of Mfp2-/- mice and age-matched control mice. The TAC expressed as nCi/cc of [18F]DPA-714 
and accompanying brain images shows slower wash out for Mfp2-/- mice compared with that of 
controls (Fig. 5a,c) in line with the ex vivo autoradiography findings. When the TAC is expressed as 
standard uptake (SUV) value, the initial brain uptake is clearly lower for Mfp2-/- mice compared to 
control mice, whereas clearance rate from brain is slower for Mfp2-/- mice (Fig. 5b,d).   
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DISCUSSION 
Microglia can perform a multitude of tasks in the CNS depending on physiological – pathological 
conditions and adapt their gene expression profile accordingly. Although TSPO has been widely used 
as a reactive microglia-specific neuroinflammation imaging target [35-37], it is unclear which microglial 
phenotypes are actually visualized [14].  By using in vitro and in vivo approaches, we demonstrate that 
TSPO is upregulated in pro-inflammatory microglia that, however, not necessarily reside in a 
destructive brain milieu.  
In vitro, microglia can be manipulated and skewed into two extreme states, analogous to 
macrophages. The described M1 - M2 subdivision nicely reflects the Janus-like behavior of microglia 
regarding their promotion of either tissue injury (M1) or repair (M2), but it is an oversimplified concept 
and only represents extreme states [38]. We show in this study that transcript levels of TSPO only 
increase in pro-inflammatory (M1) and not in anti-inflammatory (M2) microglial cells. Although this 
suggests that TSPO rather marks a harmful inflammatory brain environment and that TSPO is not 
induced in a purely neuroprotective or regenerative brain environment, this needs to be translated in 
vivo. There are several examples of neuro-inflammatory conditions in which pro-inflammatory 
microglia prevail in which it was shown that TSPO is upregulated [29-31]. By i.c.v. injection of IL-4 we 
now elicited neuro-inflammation that was primarily characterized by increased expression of anti-
inflammatory markers. In this particular neuro-inflammatory state, the expression of TSPO was 
unchanged, further proving that by tracking TSPO only a subset of neuro-inflammatory cells are 
revealed. Although microglia with either a pro- or anti-inflammatory signature can occur in defined 
pathological conditions [27], it is now accepted that microglia in vivo mostly adopt mixed pro- and anti-
inflammatory phenotypes in neurological disorders [17, 38, 39]. It will be important to corroborate our 
findings in neurological disease states in which the microglial phenotypes have been well 
characterized. For example, in a mouse model of ALS it was shown that M2 microglia are abundant in 
the early phase, whereas M1 microglia dominate at end stage of disease [40].  
 
This study also demonstrates that TSPO levels are clearly induced in vivo in a mouse model of 
peroxisomal MFP2 deficiency that develops robust neuroinflammation [17]. The results from IHC 
staining were confirmed by in vitro and ex vivo autoradiography with [18F]DPA-714 demonstrating 
increased TSPO-specific binding in several brain areas of Mfp2-/-  mice in comparison with control 
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mice.  The in vivo PET imaging data were more difficult to interpret probably due to the limited 
resolution of our micro PET scanner, although tracer clearance rate from the brain of Mfp2-/- mice was 
slower compared to control mice as was clearly demonstrated by both the nCi/cc and SUV curves. 
This is indicative for a higher target expression in brain tissue of Mfp2-/- mice, but a higher tracer 
metabolism rate cannot be excluded. The difference between nCi/cc and SUV curves can be 
explained by a different brain-to-total-body mass ratio for Mfp2-/- versus control mice which influences 
the SUV values. Mfp2-/- mice are generally 25% smaller than control mice [41]. 
The cellular and molecular characteristics of the inflammatory response in Mfp2-/- mice were previously 
extensively characterized [17]. It is noteworthy that the massive increase in myeloid cells was not due 
to infiltration of peripheral monocytes. Furthermore, the microenvironment in Mfp2-/- brain deviates 
from the milieu in neurodegenerative disorders as there is neither neuronal loss nor oxidative stress 
during the entire lifespan of Mfp2-/- mice despite the robust neuroinflammatory response [17]. Although 
the expanded microglia population expressed mixed pro- and anti-inflammatory markers, it should be 
noted that Mfp2-/- microglia do not upregulate neurotoxic and oxidative stress markers such as Nos2, 
Il6 and Icam1 [16, 17]. Thus, our data reveal that TSPO labels pro-inflammatory microglia that do not 
have a neuro-destructive character.  
In some but not all neuroinflammatory models, TSPO was shown to be upregulated in astrocytes in 
addition to microglia [6, 11, 42, 43]. In the Mfp2-/- brain, only a minority of astrocytes showed elevated 
TSPO levels, which is in contrast to microglia that virtually all induce TSPO. This supports the 
hypothesis that transition of resident microglia, and not astrocytes [44], from a resting to an activated 
phenotype principally underlies the increased TSPO expression.   
Taken together, the in vitro data showing that TSPO expression is not increased in anti-inflammatory 
circumstances supports its use as a marker for pro-inflammatory microglia imaging. However, TSPO 
upregulation does not distinguish whether microglia develop a neuro-destructive signature or not. An 
additional caveat regarding TSPO is that a human TSPO polymorphism with a trimodal distribution in 
binding affinity (high-affinity, low-affinity and mixed affinity binders) was uncovered for several TSPO 
ligands [45]. This implicates that knowledge of binding status is needed to correctly quantify TSPO 
expression using these PET ligands in humans [45].  Also the fact that the particular function of TSPO 
in mounting the inflammatory response remains obscure, is a drawback for its use as a biomarker. 
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Therefore, it is highly desirable to identify new targets that allow specific visualization of neurotoxic 
microglia. P2X7, for which versatile radiotracers were already developed, might be a good marker 
besides other candidates [46, 47]. In addition, in view of the therapeutic potential to convert pro-
inflammatory into anti-inflammatory microglia [27], there is also a need to selectively detect the latter 
microglia by in vivo imaging in order to assess the therapeutic benefit. Given the ill-defined molecular 
phenotype of healing microglia [27], this will be a more difficult task.  
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FIGURE LEGENDS 
 
Figure 1: Tspo transcript levels are increased in microglia during pro-inflammatory but not 
anti-inflammatory signaling. 
(a-c) Analysis of transcripts levels by qRT-PCR to validate the pro-inflammatory M1 condition after 
LPS treatment and the anti-inflammatory M2 state after IL-4 treatment. The typical pro-inflammatory 
genes Tnfa (a) and iNOS (b) were only upregulated after LPS treatment and the anti-inflammatory 
gene Arg1 (c) was only upregulated in IL4-treated (M2) microglia (d) Tspo transcript levels are only 
significantly increased in M1-activated microglia but not in M2-activated microglia. Data are presented 
as mean ± SEM (n=3/group). *P < 0.05; ***P < 0.001. 
 
Figure 2: Tspo transcript levels remain unchanged after IL-4 i.c.v. injections. 
(a-d) With the exception of iNOS (b) the expression of typical pro-inflammatory markers Tnfa (a), Il1b 
(c) and Il6 (d) were not altered in the frontal cortex after IL-4 injections in the third ventricle. (e-g) 
Transcripts levels of anti-inflammatory markers such as Arg1 (e) and Fizz1 (f) were markedly 
increased. The Ym1 M2 marker was not significantly altered (g). (h) Transcript levels of Tspo remain 
unchanged after IL-4 injections in the third ventricle. Data are presented as mean ± SEM (n=5/group). 
**P < 0.01; ***P < 0.001. 
 
Figure 3: Widespread increased TSPO transcript and protein levels in Mfp2-/- versus control 
brain predominantly localize in Mfp2-/- microglia. 
(a) qRT-PCR analysis shows induced Tspo transcript levels in brainstem of Mfp2-/- mice as compared 
to age-matched controls at 12 weeks of age. Data are presented as mean ± SEM (n=3/group), **P < 
0.01. (b-g) IHC staining shows virtually no immunoreactivity for TSPO (green) in CNS of wild type mice 
(b-d) but strong upregulation in Mfp2-/- brain (e-g), shown for brainstem, colliculus and thalamus. (h,i) 
IHC of TSPO (green) and Iba1 (red) to mark microglial cells. In healthy brain (h) TSPO levels are 
minimal so co-localization with Iba1+ microglia is not visible. In Mfp2-/- mice (i) TSPO immunoreactivity 
co-localizes with nearly all Iba1+ microglia (orange). Merged picture and separate channels for Iba1 
and TSPO are shown. (j,k) IHC of TSPO (green) and GFAP (red) to mark astroglia.  Astrocytes of 
control mice (j) minimally express GFAP and TSPO. In CNS of Mfp2-/- mice (k) only few GFAP+ 
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reactive astrocytes colocalize with TSPO protein (orange). Merged picture and separate channels for 
GFAP and TSPO are shown. Representative pictures are shown from colliculus region. 
 
Figure 4: In vitro and ex vivo autoradiography of brain slices of Mfp2-/- and control mice using 
[18F]DPA-714. (a, b) Sagittal brain sections of Mfp2-/- (a) and age-matched control (b) mice were 
incubated with [18F]DPA-714. Significantly higher uptake is observed in brain sections of Mfp2-/- mice. 
(c,d) [18F]DPA-714 binding was blocked in the presence of 20 µM PK11195 (d). (e-h) Ex vivo 
autoradiography of sagittal brain sections of Mfp2-/- (e,g) and age-matched control (f,h) mice at 30 (e, 
f) and 60 (g, h) min after [18F]DPA-714 injection. Significantly higher uptake is observed in brain 
sections of Mfp2-/- mice as compared to control at both 30 and 60 min after tracer injection (P < 0.01; 
two-tailed, un-paired student t-test).  
 
Figure 5: MicroPET in Mfp2-/- and control mice using [18F]DPA-714.  
(a,b) Time activity curves (TACs) expressed as nCi/cc (a) and standard uptake value (SUV g/ml) (b) 
as a function of time post tracer injection. (c,d) Accompanying brain images of both Mfp2-/- and control 
mice. n =6/group. 
 
Supplementary Figure 1: Confirmation of purity of primary microglia cultures.  
Percentage of CD11b positive cells (microglia) in primary cultures after gating for live cells. Data are 
presented as mean ± SEM (n=3). 
 
Supplementary Figure 2: Tspo transcript levels are increased in pro-inflammatory microglia 
polarized by using IL-1β/IFNγ. 
(a-c) Analysis of transcripts levels by qRT-PCR confirms that IL-1β/IFNγ treated (M1) microglia in vitro 
induce expression of typical pro-inflammatory genes such as Tnfa (a) and iNOS (b) and not the anti-
inflammatory gene Arg1 (c). (d) Tspo transcript levels are significantly increased in IL-1β/IFNγ treated 
(M1) microglia. Data are presented as mean ± SEM (n=4/group). *P < 0.05; ***P < 0.001. 
 
Supplementary Table: Primer and probe sequences used for qRT-PCR. 
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